LGND — Ligand Pharmaceuticals Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual balance sheet for Ligand Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	341	212	170	256	734
Net Total Accounts Receivable
Net Total Receivables	91.6	35	39.3	42.4	61
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	465	264	237	332	832
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	53.3	27.5	25.1	24.8	10.8
Net Goodwill
Net Intangible Assets
Long Term Investments
Other Long Term Assets
Total Assets	1,298	763	787	942	1,561
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	41.7	98.8	16.8	37.1	37.4
Long Term Debt
Total Long Term Debt
Total Debt
Deferred Income Tax
Total Other Liabilities
Total Liabilities	476	165	86.3	111	543
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	821	597	701	830	1,017
Total Liabilities & Shareholders' Equity	1,298	763	787	942	1,561
Total Common Shares Outstanding